---
title: "Neuphoria Therapeutics Inc. (NEUP.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/NEUP.US.md"
symbol: "NEUP.US"
name: "Neuphoria Therapeutics Inc."
industry: "生物技术"
---

# Neuphoria Therapeutics Inc. (NEUP.US)

| Item | Detail |
|------|--------|
| Industry | 生物技术 |
| Location | 美股市场 |
| Website | [www.neuphoriatx.com](https://www.neuphoriatx.com) |

## Company Profile

Neuphoria Therapeutics Inc.是一家临床阶段的生物制药公司，专注于发现和开发用于治疗中枢神经系统疾病的新型别构离子通道调节剂，位于澳大利亚。其主要产品候选药物包括 BNC210，这是一种选择性负别构调节剂，针对α7 受体，用于治疗社交焦虑症；目前处于治疗创伤后应激障碍的 2b 期临床试验中。该公司还开发了 BNC101，这是一种已完成 1 期临床试验的单克隆抗体，针对癌症干细胞；以及 BNC105 用于癌症治疗。此外，它还开发了 NextGen，目前处于多种中枢神经系统适应症的临床前试验阶段；以及 Kv3.1/3.2 激动剂，正在进行临床前试验，以治疗精神分裂症和自闭症...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-21T04:30:15.000Z

**Overall: B (0.38)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 47 / 403 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 2161.41% |  |
| Net Profit YoY | 31.04% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 0.79 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 23.45M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 14.99M |  |


**Multi Score**: B

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -26.07% | E |
| Profit Margin | -37.79% | E |
| Gross Margin | 0.00% | E |

#### Growth Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 2161.41% | A |
| Net Profit YoY | 31.04% | B |
| Total Assets YoY | 101.44% | A |
| Net Assets YoY | 116.04% | A |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -264.60% | D |
| OCF YoY | 2161.41% | A |

#### Operating Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.55 | C |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 18.85% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Neuphoria Therapeutics Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-26.07%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-37.79%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "A",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "2161.41%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "31.04%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "101.44%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "116.04%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-264.60%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "2161.41%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "C",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.55",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "18.85%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | ADMA生物制药 (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | Rigel制药 (US.RIGL) | A | A | A | C | B | A |
| 05 | OpGen (US.OPGN) | B | A | A | A | B | A |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -4.14 | 350/604 | 3.43 | 2.44 | 2.21 |
| PB | 0.79 | 68/604 | 1.72 | 0.66 | 0.55 |
| PS (TTM) | 1.56 | 39/604 | 12.99 | 1.38 | 0.86 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-12-05T05:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 33% |
| Overweight | 1 | 33% |
| Hold | 1 | 33% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.35 |
| Highest Target | 20.00 |
| Lowest Target | 2.30 |

## References

- [Company Overview](https://longbridge.com/en/quote/NEUP.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/NEUP.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/NEUP.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.